Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3759 in EGFR-mutant NSCLC with CNS Metastases (China, Phase I/II)
CTR20170498Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zorifertinib in non-small cell lung cancer (NSCLC), central nervous system metastases, Carcinomatous Meningitis (CM), sponsored by AstraZeneca. Started Oct 2017; status: completed.
02
Drugs
zorifertinib
03
Conditions
non-small cell lung cancer (NSCLC)central nervous system metastasesCarcinomatous Meningitis (CM)
Beyond the preview
Go deeper on CTR20170498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170498.